when were glp 1 drugs approved Only one in 12 remain on a GLP-1 drug for obesity at three years Overview of GLP-1s

Protective effect of brain-derived neurotrophic factor on pancreatic islets in obese diabetic mice

The results indicated that DSePA treatment significantly improved the asymptomatic survival time of mice against RP and lowered the incidence of RP in the irradiated mice

Current clinical evidence suggests that starting GLP-1 therapy in gastroparesis requires careful medical evaluation and baseline gastric function assessment, not automatic exclusion from treatment

It is a core component of an already FDA-approved commercial drug

Crucially, the principle of hormesis dictates that the benefits of hormetins are confined to a low-dose window

R., Haddadi, M., Shivanandappa, T